LUND, SWEDEN ― Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy. Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.
The study included 100 serum samples – 50 NSCLC and 50 controls – and was performed to assess the technical performance of the IMMray™ platform in lung cancer. As a consequence of the encouraging high diagnostic accuracy of 95% obtained with IMMray™ during this project, the parties now plan for continued collaboration by adding larger studies to confirm these preliminary findings.
“Since IMMray™ has previously demonstrated similar high (98%) accuracy in detecting pancreatic cancer, the results from this study strengthen our belief that IMMray™ has the potential to become a standard common platform for cancer diagnosis based on blood samples, and we are very much looking forward to the next steps of this collaboration”, CEO Mats Grahn said in a statement.
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.